B-MYB is an ubiquitous protein required for mammalian cell growth. In this report we show that B-MYB transactivates its own promoter through a 120 bp segment proximal to the transcription start site. The B-MYB-responsive element does not contain mybbinding sites and gel-shift analysis shows that SP1, but not B-MYB, protein contained in SAOS2 cell extracts binds to the 120 bp B-myb promoter fragment. B-MYBdependent transactivation is cooperatively increased in the presence of SP1, but not SP3 overexpression. When the SP1 elements of the B-myb promoter are transferred in front of a heterologous promoter, an increased response to B-MYB results. In contrast, c-MYB, the prototype member of the Myb family, is not able to activate the luciferase construct containing the SP1 elements. With the use of an SP1-GAL4 fusion protein, we have determined that the cooperative activation occurs through the domain A of SP1. These observations suggest that B-MYB functions as a coactivator of SP1, and that diverse combinations of myb and SP1 sites may dictate the responsiveness of myb-target genes to the various members of the myb family.
Introduction
B-MYB is a member of a family of transcription factors, which include c-MYB and A-MYB, that interact with DNA through the consensus sequence pyAACG/TG (Lyon et al., 1994; Nomura et al., 1988) . Both A-MYB and c-MYB possess a strong transcription activating domain, of the acidic type, and several studies showed them to transactivate target genes eciently (Golay et al., 1994; Trauth et al., 1994; Ness et al., 1989) . Although it was suggested that B-MYB represses cellular promoters acting through the myb site (Foos et al., 1992; Marhamati and Sonenshein, 1996) , we and others have shown that B-MYB can indeed activate promoters, both via DNA binding-dependent and -independent mechanisms, following phosphorylation mediated by cyclin A/ E-cdk2 kinase (Sala et al., 1997; Lane et al., 1997; Ziebold et al., 1997 ). It appears that B-MYB transactivating ability depends on the availability of speci®c cofactors. In fact, it has been shown that B-MYB transcriptional activity varies with the cell type, and is associated with the binding of cellular proteins to its conserved region in the C-terminus of the protein (Tashiro et al., 1995) .
Molecular and biological data gathered in dierent laboratories indicate that B-MYB is a positive regulator of cell proliferation. B-MYB expression is required for the growth and survival of cells of dierent origins, and deregulated expression of B-MYB leads to abnormal cell growth and to inhibition of cellular dierentiation (Arsura et al., 1992; Sala and Calabretta, 1992; Lin et al., 1994; Raschella' et al., 1995; Bies et al., 1996) . We and others have observed that abnormal expression of B-MYB results in apoptosis under certain circumstances, suggesting that its activity is connected to cell cycle control and cellular homeostasis (Bies and Wol 1995, and unpublished data) . These results imply that B-MYB should be regarded as a potential proto-oncogene, although it must be emphasized that B-MYB promotes DNA synthesis of certain, but not all, mammalian cell lines (Lyon et al., 1994; Sala et al., 1997) . Like other proto-oncogenes involved in cell-cycle regulation, B-MYB is subjected to the control of negative factors that may dictate the cell-type dependence of B-MYB eects. We have shown that B-MYB is engaged in mutually antagonistic interactions with growth suppressor proteins such as p53 and p107, in the latter case mediated by protein to protein interaction (Lin et al., 1994; Sala et al., 1996a,b) . In addition, B-MYB promotes DNA synthesis of the SAOS2 human osteosarcoma cell line only in the presence of cyclin A or E, indicating that cyclin-directed phosphorylation of B-MYB protein also may be necessary to regulate cell cycle progression (Sala et al., 1997) .
In the present work, we investigated in more detail the mechanism by which B-MYB transactivate promoters without binding to DNA. In a previous paper we showed that human B-MYB regulates its own transcription, but the mechanism underlying the autoregulation phenomenon remained elusive (Sala et al., 1996b) . Here, we present evidence suggesting that B-MYB cooperates with the transcription factor SP1, resulting in the synergistic activation of the B-myb promoter.
Results

Delineation of a B-MYB-responsive region in the human B-myb promoter
Transient transfection assays with B-myb promoter deletion constructs driving the luciferase gene indicated that B-MYB could transactivate its own promoter, and that the responsive region mapped between nt 7240 and nt 7360, starting from the initiation of translation (Figure 1a) . These results were consistent with preliminary observations indicating that B-MYB protein transactivates both murine and human B-myb promoter (Sala et al., 1996b; R Watson, personal observation) . It is interesting to note that deletion of the promoter region between nt 7617 and nt 7537 results in a drastic decrease of activity that is regained following further deletion up to nt 7360. This phenomenon is likely due to the presence of enhancer/repressor elements dispersed in the promoter sequences. To prove that the 7240 construct was not activated by B-MYB because it lacked basal promoter elements, we cotransfected it with E2F1, whose site is contained within the 7240 segment. E2F1 eciently activated the 7240 construct, suggesting that the inability of B-MYB to activate it was due to the loss of B-MYB-responsive sites, rather than the loss of basal transcription elements (Figure 1b) .
Sp1, but not SP3, synergizes with B-MYB in transactivating the B-myb promoter
Inspection of the B-myb promoter region that responded to B-MYB activity revealed that it was rich in GC bases and that it contained several potential SP1, but not myb, sites. SP1 is a ubiquitous transcription factor whose binding sequence is present in most growth regulatory genes that do not contain TATA boxes (Kadonaga et al., 1987; Blake et al., 1990) . It was reported previously that SP1 cooperates with several transcription factors, resulting in potentiation of SP1-dependent transactivation (Seto et al., 1993; Merika and Orkin, 1995; Lin et al., 1996) . We speculated that a similar mechanism might be responsible for B-myb gene autoregulation. A corollary of this hypothesis is that concurrent overexpression of B-MYB and SP1 should result in cooperative transactivation. We cotransfected the 7360 B-myb promoter, linked to the luciferase gene, with CMV-B-MYB and CMV-SP1. To check for speci®city, we also used an expression vector encoding SP3, which is a member of the SP family that can activate certain promoters, although it also can act as a negative regulator of SP1 (Majello et al., 1994; Prowse et al., 1997; Dennig et al., 1996) . SP3 was less active than SP1 in activating the B-myb promoter (twofold versus ®vefold, respectively), and only SP1 cooperated with B-MYB, demonstrating a speci®c functional interaction between the two transcription factors (Figure 2) . The strong inhibition of B-MYB-dependent transactivation by SP3 likely was because of competition with endogenous SP1, consistent with the hypothesis that B-MYB operates as an SP1-speci®c cofactor. The SP1 sites in the B-myb promoter confer responsiveness to B-MYB, but not to c-MYB overexpression when transferred in front of an heterologous promoter
We wanted to verify that B-MYB-dependent transactivation of the B-myb gene was associated with the presence of SP1 sites. Considering that the responsive region of the B-myb promoter contains ten potential SP1 sites, we decided to transfer a portion of it, containing a cluster of canonical SP1 sites, in front of an heterologous promoter. We prepared a 28 bp double stranded oligonucleotide that contained three closely spaced SP1 sites, located between nt 7277 and nt 7304 from the translation start site, and subcloned it in the wild-type or mutant conformation, into the polylinker region of the pGL2-promoter vector. We named the two plasmids pglPROBMYB(WT) and pglPROBMYB(MUT), respectively. B-MYB protein activated pglPROBMYB(MUT) plasmid, which contained mutated SP1 sites, substantially less than pglPROBMYB(WT) plasmid, demonstrating that B-MYB transactivates, at least in part, through the SP1 site ( Figure 3a ). Gel shift analysis with the 28 bp double stranded oligonucleotide probe containing the putative SP1 sites showed that nuclear proteins extracted from SAOS2 cells bound the probe and were competed-out by double stranded oligonucleotides containing a wild-type, but not mutated, SP1-motif ( Figure 3b , lanes 2, 3 and 4); SP1 was identi®ed positively by the use of a speci®c antibody that supershifted the putative SP1 complex (Figure 3b , lane 6). C-MYB was unable to activate the pglPROB-MYB(WT) plasmid (Figure 3c ), whereas it readily transactivated the pGL2-promoter vector containing the mim-1 promoter site A (Figure 3d ). Immunoprecipitation/Western blot with B-MYB and c-MYB antibodies revealed that both proteins were expressed following transient transfection in SAOS2 cells ( Figure  3e) . B-MYB protein transiently transfected in SAOS2 cells was able to bind to the site A of the mim-1 promoter (Figure 4 ). In contrast, it did not bind to the 120 bp fragment representative of the responsive region of the B-myb promoter because lysates of SAOS2 cells transfected with B-MYB did not show a speci®c supershift when a B-MYB antibody was added to the mixture (Figure 5a ). This data is in accord with the fact that no extra bands were detected when lysates of B-MYB-transfected cells were compared to untransfected cells (Figure 5b ). To con®rm and extend this result, a gel shift assay was also performed with a 250 bp fragment that contained the responsive region plus additional promoter sequence toward the 3' end. The probe was mixed with puri®ed SP1 protein or in vitro produced B-MYB protein. This assay con®rmed that SP1, but not full-length B-MYB or a B-MYB protein deleted in the carboxyl-terminus, was able to bind to the probe (Figure 5c ). In vitro translated B-MYB proteins were detectable with a B-MYB speci®c antibody (Figure 5d ).
An oligonucleotide containing the myb site cannot suppress B-MYB autoregulatory activity
To exclude that B-MYB transactivation was due to cryptic myb-binding sites dispersed in the vector sequences, we transiently transfected SAOS2 cells with the pglPROBMYB(WT) or PGL-MIM1 vectors. The two reporters dier from each other only for the presence of one myb binding site (PGL-MIM1) or three SP1 sites [pglPROBMYB(WT)] cloned in the SmaI site of the PGL-promoter vector. The reporter plasmids were cotransfected with the CMV B-MYB vector plus or minus an excess of a double stranded oligonucleo- 1 and 3) , B-MYB antibody (lane 2) or control antibody (lane 4). The immunoprecipitated material was resolved on a 7.5% mini-gel, blotted onto nitrocellulose and Western-blotted with a mixture of B-MYB and c-MYB antibodies tide containing the myb site A from the mim-1 promoter. Our prediction was that activation which is dependent upon binding of B-MYB to its site would be suppressed because B-MYB protein should be displaced by the oligonucleotide containing the myb site. On the other hand, transactivation which is independent from binding of B-MYB to DNA should not be aected. The result of this experiment shows that B-MYB-driven activation is highly inhibited by the mybbearing oligonucleotide when the myb site is cloned upstream the SV40 minimal promoter of the PGL vector (Figure 6a) . In sharp contrast, the response to B-MYB is not aected when the myb site is replaced by SP1 sites (Figure 6b ). This argues against the hypothesis that undetected myb sequences could mediate B-MYB transactivation of pGL-promoterbased vectors.
B-MYB cooperates with the transactivating`A' domain of SP1, but not with that of E1A, VP16, or NF-KB
A fusion protein, consisting of the SP1 transactivating domain`A' linked to the GAL4 DNA binding domain, was cotransfected with CMV-B-MYB and with a reporter gene containing GAL4 binding sites linked to the CAT gene. This experiment showed that B-MYB induced synergistic transactivation of the reporter construct when concurrently overexpressed with Gal4/ SP1, but did not with GAL4 alone or with Gal4/E1A, Gal4/VP16 or Gal4/p65. This experiment indicates that the functional interaction between B-MYB and SP1 is speci®c and suggests that B-MYB does not require to bind to DNA in order to enhance SP1 transcriptional activity (Figure 7) .
Discussion
In this study we present evidence that B-MYB activate its own transcription through SP1 sites present in the 7360/7240 region of the B-myb promoter. Although some reports suggest that B-MYB transactivates promoters through direct binding to DNA, we have been able to demonstrate in our laboratory that B-MYB activity also can be detected in the absence of typical myb binding sites in promoters driving genes potentially involved in growth control (Sala et al., 1997) . It is important to de®ne the mechanism by which B-MYB transactivates these genes because they may be the eectors of B-MYB positive in¯uence on cell proliferation. The results in this study suggest that one mediator of B-MYB transcriptional activity is SP1, at least in the case of B-MYB-dependent activation of its own promoter. SP1 is a general transcription factor that is ubiquitous and expressed abundantly in mammalian cells (Berg, 1992) . It has been recognized as a basal factor whose sites are present in TATA-less promoters, and it has been reported that SP1 often controls initiation of transcription from those promoters (Azizkhan et al., 1993) . The addition of SP1 sites may confer cell-cycle regulated activity to certain genes, and recent evidence suggests that SP1 is involved in transcription of late G1 genes. SP1 and E2F1 have been shown to be associated physically during the G1/S transition of the cell cycle, and to activate promoters cooperatively (Lin et al., 1996) . B-MYB expression peaks in late G1 (Lam et al., 1992 ) and it appears likely that B-MYBdependent activation of late G1 genes, such as cdc2 and B-myb, might occur through a mechanism involving SP1. Two major conclusions can be drawn from our studies: (1) The presence of myb sites is not sucient to make a promoter respond to B-MYB. In fact, B-MYB is unable to transactivate the mim-1 promoter in its wild-type conformation (data not shown), although it contains B-MYB binding sites (Figure 4) . Nevertheless, the myb-binding sequence becomes responsive to B-MYB when it is cloned upstream the SV40 minimal promoter ( Figure 6a) ; (2) B-MYB, but not c-MYB, is able to transactivate promoter sequences through SP1 sites in the contest of the human B-MYB promoter (Figure 3) , implying that the two proteins may activate distinct sets of genes. In this regard, B-MYB and v-MYB proteins have previously been reported to regulate gene expression by indirect mechanisms (Ibanez and Lipsick, 1990; Engelke et al., 1995; Kamano and Klempnauer, 1997) . Interestingly, Ibanez and collegues have demonstrated that v-MYB activates the thymidine kinase promoter, but not the SV40 promoter, through SP1 elements. The authors also suggested that the presence of other promoter elements, beside SP1-binding sites, was necessary for indirect activation of the TK promoter by v-MYB (Engelke et al., 1995) . In the light of these and our own results, we may conclude that MYB proteins are able to activate dierent promoters indirectly and that the SP1 site is crucially related to this activity. The promoter context determines whether or not a particular gene is responsive to a speci®c Myb protein.
SP1 has been shown to associate with transcription factors implicated in the cell-cycle and growth control, and one could hypothesize that the binding of one or more partners results in the formation of multiprotein complexes with distinct activities, depending on the speci®c phase of the cell cycle.
The mechanism by which B-MYB acts through SP1 sequences is not de®ned at the present time, although it is likely that the two proteins form a complex in vivo. In fact, in vitro translated B-MYB and SP1 protein do not bind to each other, but a weak interaction can be detected in certain cell lines or when the two proteins are overexpressed in SAOS2 cells (not shown). This data suggests that B-MYB and SP1 participate in a protein complex that requires the presence of other cellular factors. The multi-protein complex may directly aect the transcription rate or interfere with protein translocation or degradation. This is consistent with previous results showing that B-MYB transcriptional activity correlates with the binding of cellular proteins to its C-terminus (Tashiro et al., 1995) . The data presented in this report support our hypothesis that B-MYB is an activator of genes promoting the G1/S transition, and that this function may be linked to the positive eect induced by B-MYB on DNA synthesis. It will be of interest to analyse the role of SP1 in B-MYB-dependent activation of other genes, such as cdc2 and the HIV-LTR.
Materials and methods
Cell lines
The SAOS2 cell line was purchased from ATCC and was cultured in DMEM medium supplemented with 15% fetal calf serum.
Plasmids
CMV-BMYB, pMbM1 (containing the c-myb cDNA driven by the SV40 promoter and enhancer), CMV-SP1, and CMV-SP3 have been described (Lin et al., 1994; Clarke et al., 1988; Majello et al., 1994) . The plasmid pGL2-promoter was purchased from Promega. The plasmid CMV-C-MYB, containing the c-myb cDNA driven by the CMV promoter, was a kind gift of Dr Bruno Calabretta and was obtained by subcloning the human c-myb cDNA into the polylinker region of the plasmid pCDNA3 (inVitrogen). The human B-myb promoter (i.e. the 7910 construct, pGLBMYB) was described (Lam et al., 1995) . Deletions of this fragment were made by ®rst subcloning into pT7T3 18U (Pharmacia) using¯anking XmaI sites, generating pT7HB-myb. The deletion constructs were made as follows: 7708: pT7HB-myb was cut with NruI and BamHI (cuts 5' of the promoter sequence) and subcloned into pGL2-Basic using SmaI/BgIII. 7617: cut pT7HB-myb with BsaI, ®lled in 5' overhang with Klenow enzyme and recut with BamHI; subcloned into SmaI/BgIII cut pGL2-Basic. 7537: cut pT7HB-myb with XcmI, removed 3' overhang with T4 DNA polymerase and recut with BamHI; subcloned into SmaI/BgIII cut pGL2-Basic. 7360; cut pT7HB-myb with NotI, ®lled in 5' overhang with Klenow enzyme and recut with BamHI; subcloned into SmaI/BgIII cut pGL2-Basic. 7240: cut pT7HB-myb with BssHII, ®lled in 5' overhang with Klenow enzyme and recut with BamHI; subcloned into SmaI/BgIII cut pGL2-Basic. The pglPROB-MYB(WT) and pglPROBMYB(MUT) were generated by cutting the pGL-promoter vector with SmaI and ligating a 30 bp double stranded oligonucleotide representative of the B-MYB promoter from nt 7304 to nt 7277, with wildtype (CAGGCCCCGCCCCGCCCCGCCCCGAGCT) or mutated (CAGGCCTTGCCTTGCCTTGCCCCGAGCT) SP1 sites, respectively. The pgl-MIM-1 construct was obtained by subcloning a double stranded oligonucleotides encompassing the mim-1 promoter site A (GCTAAAAATCGTTATAATGTGTCGA) within the SmaI site of the pGL-promoter vector.
Transient transfections and luciferase assay
Transient transfections were performed according to the calcium phosphate precipitation method in 35 mm plates. 1 mg of the dierent promoter constructs was cotransfected with 1 mg of empty CMV vector or with 1 mg of CMV-B-MYB per well. Luciferase assay was carried out with the aid of the Luciferase Assay Kit (Promega) following manufacturer's instructions. To compensate for differences in transfection eciency, each experimental point was performed in triplicate, and each set of experiments was repeated at least four times with dierent plasmid preparations. Luciferase activity was measured with the aid of a scintillation counter and it is expressed as counts per minute (c.p.m.).
GAL4-SP1 fusion protein and CAT assay
The G5E1b reporter plasmid and the pSG424 plasmids have been described (Lillie and Green, 1989; Sadowski and Ptashne, 1989) . The GAL4Sp1, GAL4E1A, GAL4Vp16, and GAL4p65 also have been described (De Luca et al., Figure 4) . Note that the two reporters are both derived from the pGL-promoter vector. They dier from each other only for the presence of an oligonucleotide containing the myb site A (PGL-MIM1) or an oligonucleotide containing three SP1 sites from the B-myb promoter (pglPROBMYBwt). Transfections were performed in triplicate as described in Figure 1 . Standard deviation is indicated by the error bars Figure 7 Cooperative activity between B-MYB and the transactivating domain A of SP1. 5 mg of G5E1b were cotransfected with 5 mg of pSG424 or GAL4Sp1, with 1 mg of GAL4E1A or GAL4p65 and with 200 ng of GAL4Vp16 as indicated. After 36 h, SAOS2 cells were collected and subjected to CAT assay. Increasing amounts of B-MYB expression plasmid enhanced only the activation observed for Gal4-Sp1. The histogram represents the mean of three independent transfections. The triangles indicate addition of increasing amount of CMV-B-MYB plasmid. Standard deviation is indicated 1996 and references therein). CAT assay was performed as described (Majello et al., 1994) .
Gel Shift
SAOS2 cells extracts were prepared by incubating 5610 6 cells in 100 ml of lysis buer (20 mM HEPES (pH 7.6), 20% glycerol, 400 mM NaCl, 1.5 mM MgCl 2 , 2.5 mM DTT 1 mM PMSF) for 30' followed by three cycles of rapid freezing and thawing. 5 mg of proteins were mixed with 32 P-labeled double stranded oligonucleotide probes representative of the B-MYB promoter [the oligonucleotide used were the same as those subcloned to generate the pglPROB-MYB(WT) and pglPROBMYB(MUT) constructs]. A restriction fragment from nt 7240 to nt 7360 of the human B-MYB map was isolated by digesting the pGLBMYB plasmid with BssHII and NotI, labeling with 32 P, and mixing the probe with SAOS2 nuclear extracts transfected with empty CMV vector or CMV-B-MYB. The reactions were run onto a 4% native polyacrylamide gel and exposed on X-ray ®lm. Double stranded oligonucleotides containing a wild-type (ATTCGATCGGGG-CGGGGCGAGC) or a mutated (ATTCGATCG-GTTCGGGGCGAGC) SP1 binding site were used as competitors. For supershift experiments, an SP1-speci®c antibody (Pep-2 Santa Cruz), or normal serum, was added to the extracts for 30 min on ice before mixing with the probe. Puri®ed SP1 protein was purchased from Promega. TNT Wheat Germ Extract (Promega) was programmed with a pCDNA3 plasmid containing the full-length B-myb cDNA or a deletion mutant obtained by cutting the B-myb cDNA with ScaI.
